Table 1.

Some of the clinical trials were designed for patients with melanoma.

Medication	Mechanism of action	Clinical trial phase	Study start date	The status	ClinicalTrials.gov identifier
DC-vaccine	Biological anti-tumoral immunity	Phase II	2002	Terminated	NCT01042366
DC-vaccine	Biological anti-tumoral immunity	Phase I	2005	Completed	NCT00125749
Binimetinib and Encorafenib	Inhibition of the MAPK pathway and BRaf gene, respectively	Phase II	2020	Not yet recruiting	NCT04221438
Pembrolizumab and Ipilimumab	Inhibition of PD-1 axis and CTLA-4 axis	Phase II	2019	Active, not recruiting	NCT03873818
Nivolumab and Ipilimumab	Inhibition of PD-1 axis and CTLA-4 axis	Phase II	2016	Active, not recruiting	NCT02970981
Pembrolizumab, Cyclophosphamide, and DC-based vaccine	Inhibiting PD-1/PD-L1 axis, inhibiting protein synthesis, and Biological anti-tumoral immunity	Phase I	2017	Recruiting	NCT03092453
Standard of care immune checkpoint inhibitors and DC-based vaccine	Inhibiting immune checkpoints and inducing biological anti-tumoral immunity	Phase I/II	2016	Active, not recruiting	NCT02678741

DC-vaccine, dendritic cell vaccine; PD-1: programmed cell death protein 1.